Insulet Launches Omnipod 5 and Omnipod Discover in Spain to Expand Tubeless Diabetes Care
Insulet Corporation has announced the commercial launch of its Omnipod® 5 Automated Insulin Delivery System and Omnipod Discover™ in Spain, marking another major milestone in the company’s international expansion strategy. The introduction of these advanced diabetes management solutions brings Insulet’s innovative tubeless insulin delivery technology to one of Europe’s largest diabetes markets, providing people living with type 1 diabetes access to automated, personalized insulin therapy designed to simplify daily disease management.
With Spain joining the growing list of countries offering Omnipod technology, Insulet continues to strengthen its global presence while advancing its mission of improving the lives of people with diabetes through innovative medical technology. Spain becomes the 26th country where Omnipod products are commercially available and the 20th country where patients can access the Omnipod 5 Automated Insulin Delivery System.
The launch reflects the company’s continued investment in expanding access to advanced diabetes technologies and supporting healthcare professionals with integrated digital tools that enhance patient care.
Expanding Global Access to Diabetes Innovation
The launch in Spain represents another important step in Insulet’s international growth strategy.
Over the past several years, the company has significantly expanded its global footprint by introducing Omnipod technology into new healthcare markets across Europe and other regions. According to Insulet, Omnipod 5 has now been launched in 15 countries within the past 18 months, demonstrating the company’s commitment to making automated insulin delivery more widely available.
This rapid expansion highlights increasing worldwide demand for diabetes technologies that reduce the daily burden associated with insulin therapy.
By entering Spain, Insulet strengthens its position as a global leader in tubeless insulin pump technology while increasing access to automated diabetes management systems for thousands of additional patients.
Addressing a Significant Healthcare Need
Diabetes remains one of the most prevalent chronic diseases worldwide, affecting millions of individuals and placing significant demands on healthcare systems.
Spain alone is home to more than 4.6 million adults living with diabetes, making it an important market for advanced diabetes management solutions.
Among these individuals are approximately 189,000 people living with type 1 diabetes, a condition in which the pancreas produces little or no insulin, requiring lifelong insulin replacement therapy.
Additionally, more than 18,500 children and adolescents between the ages of 0 and 19 in Spain are living with type 1 diabetes.
For these patients, effective insulin management is essential to maintaining healthy blood glucose levels and reducing the risk of long-term complications.
The availability of Omnipod 5 introduces a new treatment option designed to make insulin therapy more automated, personalized and convenient.
Simplifying Diabetes Management
Managing type 1 diabetes requires continuous attention throughout the day.
Patients must regularly monitor blood glucose levels, calculate insulin doses, administer insulin and respond to changing factors such as meals, physical activity, illness and stress.
These daily responsibilities can create significant physical and emotional burdens for both patients and caregivers.
Insulet developed Omnipod 5 to help reduce these challenges through automation.
The system continuously monitors glucose information and automatically adjusts insulin delivery, reducing the need for manual intervention while helping maintain blood glucose within target ranges.
By automating many routine insulin adjustments, the technology aims to improve both clinical outcomes and quality of life.
Introducing Omnipod 5
Omnipod 5 is Insulet’s latest-generation Automated Insulin Delivery (AID) system.
Unlike traditional insulin pumps that use tubing to connect the pump to the body, Omnipod features a compact, wearable Pod that delivers insulin directly without external tubing.
The lightweight Pod adheres to the skin and provides continuous insulin delivery while communicating wirelessly with compatible continuous glucose monitoring (CGM) sensors.
The absence of tubing allows users greater flexibility during everyday activities while maintaining consistent insulin administration.
The device is also waterproof, allowing many daily activities to continue without disconnecting insulin therapy.
Automated Insulin Adjustments Every Five Minutes
A key feature of Omnipod 5 is its automated insulin adjustment capability.
Using data received from compatible continuous glucose monitoring sensors, the system evaluates glucose trends and automatically adjusts insulin delivery every five minutes.
Rather than relying solely on preset basal insulin rates, the system continuously responds to changing glucose levels throughout the day and night.
This frequent automated adjustment helps maintain more stable glucose control while reducing both high and low blood sugar episodes.
The technology represents a significant advancement over conventional insulin therapy, which often requires frequent manual dose adjustments.
Supporting Better Glycemic Outcomes
One of the primary goals of automated insulin delivery systems is improving glycemic control.
Maintaining blood glucose within recommended target ranges can reduce the risk of both short-term complications and long-term health problems associated with diabetes.
According to Insulet, Omnipod 5 is designed to improve several important diabetes management outcomes.
These include:
- Increased time spent within target glucose range
- Reduced HbA1c levels
- Fewer episodes of high blood glucose
- Protection against low blood glucose
- More consistent overnight glucose control
These improvements may contribute to better long-term health while reducing the daily stress associated with diabetes management.
Integrated Continuous Glucose Monitoring
The Omnipod 5 system works by communicating directly with compatible continuous glucose monitoring sensors.
In Spain, the system is compatible with:
- Abbott FreeStyle Libre 2 Plus
- Dexcom G7
These sensors continuously measure glucose levels throughout the day and transmit information to the automated insulin delivery algorithm.
The system uses this real-time glucose data to determine whether insulin delivery should increase, decrease or remain unchanged.
This closed-loop communication enables proactive insulin adjustments based on changing glucose trends rather than waiting until glucose levels become dangerously high or low.
Personalized Insulin Therapy
Each individual living with diabetes has unique insulin requirements influenced by numerous factors including age, body weight, activity level, meals, illness and daily routines.
Omnipod 5 uses personalized settings that adapt insulin delivery according to each user’s individual needs.
The automated algorithm continually evaluates incoming glucose data while considering the user’s insulin profile.
This individualized approach helps create more precise insulin delivery compared with traditional fixed-dose schedules.
Personalized automation reduces the burden of frequent manual calculations while supporting more consistent diabetes management.
Omnipod Discover Enhances Clinical Care
Alongside Omnipod 5, Insulet is introducing Omnipod Discover™, its proprietary data management platform.
The software enables healthcare professionals to review patient therapy data in greater detail, supporting informed treatment decisions and ongoing diabetes management.
By organizing insulin delivery information, glucose trends and therapy performance into accessible reports, Omnipod Discover helps clinicians monitor patient progress and identify opportunities for treatment optimization.
This integrated digital platform strengthens collaboration between patients and healthcare providers while supporting more personalized care.
Supporting Healthcare Professionals
Insulet emphasizes that diabetes management is most effective when advanced technology is paired with clinical expertise.
The introduction of Omnipod Discover provides physicians, diabetes specialists and healthcare teams with enhanced visibility into patient treatment data.
Access to detailed therapy information allows providers to:
- Monitor glucose trends
- Review insulin delivery patterns
- Identify recurring challenges
- Optimize treatment settings
- Support patient education
- Improve long-term diabetes management
These capabilities may contribute to more efficient clinical visits and better-informed therapeutic decisions.
Improving Daily Quality of Life
Beyond clinical outcomes, automated insulin delivery systems seek to improve everyday living for people with diabetes.
Traditional diabetes management often requires multiple daily insulin injections, repeated glucose testing and continuous decision-making.
These responsibilities can interfere with work, school, sports, travel and sleep.
Omnipod 5 helps reduce many of these daily demands through automation.
The discreet wearable Pod eliminates the need for multiple injections while providing continuous insulin delivery without tubing.
Automatic insulin adjustments also reduce the frequency of manual corrections, allowing users greater confidence in managing their condition.
For children and adolescents, these benefits may also reduce caregiver burden while supporting greater independence.
Meeting the Needs of Spanish Patients
According to Dr. Rafael Bravo, Vice President for Global Medical Affairs at Insulet and a specialist in endocrinology, many individuals living with type 1 diabetes in Spain are seeking technologies that simplify diabetes management while improving confidence and safety.
The arrival of Omnipod 5 and Omnipod Discover addresses these needs by providing an integrated solution that combines automated insulin delivery with advanced digital health tools.
The company believes the technology will help patients better manage diabetes while reducing the physical and emotional demands associated with lifelong insulin therapy.
Leadership Highlights Continued International Growth
Pat Crannell, Senior Vice President and International General Manager at Insulet, described Spain as an important market for the company’s continued international expansion.
He noted that the launch reflects both the company’s long-term global growth strategy and its commitment to improving diabetes care worldwide.
Each new market introduction brings Insulet closer to its vision of reducing the daily burden of diabetes for people living with the condition.
The company views continued expansion as an opportunity to provide advanced diabetes technologies to more patients while strengthening partnerships with healthcare providers across international markets.
As diabetes prevalence continues to rise globally, demand for innovative medical technologies that improve disease management is expected to grow.
Automated insulin delivery systems are increasingly becoming an important component of modern diabetes care by combining wearable medical devices, continuous glucose monitoring and intelligent software algorithms into integrated treatment solutions.
With the launch of Omnipod 5 and Omnipod Discover in Spain, Insulet expands access to advanced tubeless insulin delivery technology while reinforcing its leadership in automated diabetes management.
The company’s continued investment in international expansion reflects broader efforts to improve clinical outcomes, simplify daily insulin therapy and enhance quality of life for people living with type 1 diabetes.
By bringing personalized, automated insulin delivery to more healthcare systems worldwide, Insulet continues advancing its mission of transforming diabetes care through innovation, helping patients spend less time managing their condition and more time living their lives.
Source link: https://www.businesswire.com/
